In vitro and in vivo characterization of meloxicam nanoparticles designed for nasal administration.

The nasal pathway represents a non-invasive route for delivery of drugs to the systemic circulation. Nanonization of poorly soluble drugs offers a possibility to increase dissolution properties, epithelial permeability or even bioavailability. The aim of the present study was to use in vitro methods to screen formulations which were intended for nasal application, and to perform animal experiments for recognizing the differences in plasmakinetics of intranasal- and oral-administered meloxicam nanoparticles. Due to nanonization the solubility of meloxicam elevated up to 1.2mg/mL, additionally the extent of dissolution also increased, complete dissolution was observed in 15 min. Favorable in vitro diffusion profile of meloxicam nanoparticles was observed and their epithelial permeability through human RPMI2650 cells was elevated. The pharmacokinetic parameters were significantly increased when meloxicam was administered as nanoparticles to rats either nasally (increase of Cmax 2.7-fold, AUC 1.5-fold) or orally (increase of C(max) 2.4-fold, AUC 2-fold) as compared to physical mixture of the drug and the excipients.

[1]  L. Puskás,et al.  The effect of sucrose esters on a culture model of the nasal barrier. , 2012, Toxicology in vitro : an international journal published in association with BIBRA.

[2]  Rainer H Müller,et al.  State of the art of nanocrystals--special features, production, nanotoxicology aspects and intracellular delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[3]  G. Zapantis,et al.  In vitro and in vivo percutaneous absorption of topical dosage forms: case studies. , 2005, International journal of pharmaceutics.

[4]  L. Illum,et al.  Intranasal delivery: physicochemical and therapeutic aspects. , 2007, International journal of pharmaceutics.

[5]  E. Björk,et al.  Evaluation of drug release from gels on pig nasal mucosa in a horizontal Ussing chamber. , 2002, Journal of controlled release : official journal of the Controlled Release Society.

[6]  S. Davis,et al.  Intranasal delivery of morphine. , 2002, The Journal of pharmacology and experimental therapeutics.

[7]  L. Puskás,et al.  Retinoic acid and hydrocortisone strengthen the barrier function of human RPMI 2650 cells, a model for nasal epithelial permeability , 2013, Cytotechnology.

[8]  Wei Zheng,et al.  Application of real-time cell electronic sensing (RT-CES) technology to cell-based assays. , 2004, Assay and drug development technologies.

[9]  L. Illum.  Nasal drug delivery--possibilities, problems and solutions. , 2003, Journal of controlled release : official journal of the Controlled Release Society.

[10]  Stephan Reichl,et al.  RPMI 2650 epithelial model and three-dimensional reconstructed human nasal mucosa as in vitro models for nasal permeation studies. , 2010, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[11]  Rita Ambrus,et al.  Study of the parameters influencing the co-grinding process for the production of meloxicam nanoparticles , 2011 .

[12]  Indranil Nandi,et al.  Synergistic effect of PEG-400 and cyclodextrin to enhance solubility of progesterone , 2003, AAPS PharmSciTech.

[13]  E. Bluhmki,et al.  Meloxicam: a review of its pharmacokinetics, efficacy and tolerability following intramuscular administration , 2001, Inflammation Research.

[14]  J. Ressler,et al.  New concepts for chip-supported multi-well-plates: realization of a 24-well-plate with integrated impedance-sensors for functional cellular screening applications and automated microscope aided cell-based assays , 2004, The 26th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.

[15]  Peter,et al.  In vitro cell models to study nasal mucosal permeability and metabolism. , 1998, Advanced drug delivery reviews.

[16]  G. Balogh,et al.  Sodium hyaluronate as a mucoadhesive component in nasal formulation enhances delivery of molecules to brain tissue. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[17]  Sonu Bhatia,et al.  Solubility enhancement of cox-2 inhibitors using various solvent systems , 2003, AAPS PharmSciTech.

[18]  U. Busch,et al.  Pharmacokinetics of meloxicam in animals and the relevance to humans. , 1998, Drug metabolism and disposition: the biological fate of chemicals.

[19]  L. Šoltés,et al.  Hyaluronic Acid: A Natural Biopolymer , 2011 .

[20]  Barrett E. Rabinow,et al.  Nanosuspensions in drug delivery , 2004, Nature Reviews Drug Discovery.

[21]  F. Ahsan,et al.  Evaluation of human nasal RPMI 2650 cells grown at an air-liquid interface as a model for nasal drug transport studies. , 2008, Journal of pharmaceutical sciences.

[22]  D. Türck,et al.  Meloxicam oral suspension: a treatment alternative to solid meloxicam formulations , 2001, Inflammation Research.

[23]  Alexandra Kroll,et al.  Current in vitro methods in nanoparticle risk assessment: limitations and challenges. , 2009, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[24]  J Kristl,et al.  Investigation of preparation parameters to improve the dissolution of poorly water-soluble meloxicam. , 2009, International journal of pharmaceutics.

[25]  Y. Chien,et al.  Nasal systemic drug delivery , 1989 .

[26]  H. Wolburg,et al.  Epithelial and endothelial barriers in the olfactory region of the nasal cavity of the rat , 2008, Histochemistry and Cell Biology.

[27]  N. Davies,et al.  Clinical Pharmacokinetics of Meloxicam , 1999, Clinical pharmacokinetics.

[28]  R. Kinget,et al.  Nasal mucoadhesive drug delivery: background, applications, trends and future perspectives. , 2005, Advanced drug delivery reviews.

[29]  Zhong Zuo,et al.  An approach for rapid development of nasal delivery of analgesics--identification of relevant features, in vitro screening and in vivo verification. , 2011, International journal of pharmaceutics.

[30]  M. Morgen,et al.  Polymeric Nanoparticles for Increased Oral Bioavailability and Rapid Absorption Using Celecoxib as a Model of a Low-Solubility, High-Permeability Drug , 2011, Pharmaceutical Research.

[31]  B. Luppi,et al.  Drug "supersaturation" states induced by polymeric micelles and liposomes: a mechanistic investigation into permeability enhancements. , 2013, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[32]  L. Puskás,et al.  A cell-microelectronic sensing technique for the screening of cytoprotective compounds , 2010 .

[33]  M. Brandl,et al.  Impact of FaSSIF on the solubility and dissolution-/permeation rate of a poorly water-soluble compound. , 2012, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[34]  Z. Nemeth,et al.  Structure and drug release of lamellar liquid crystals containing glycerol. , 2003, International journal of pharmaceutics.

[35]  M. Deli,et al.  Potential use of tight junction modulators to reversibly open membranous barriers and improve drug delivery. , 2009, Biochimica et biophysica acta.

[36]  Cynthia K. Brown,et al.  FIP/AAPS guidelines to dissolution/in vitro release testing of novel/special dosage forms , 2008, AAPS PharmSciTech.

[37]  M. Fornai,et al.  Efficacy and Tolerability of Meloxicam, a COX-2 Preferential Nonsteroidal Anti-Inflammatory Drug , 2002 .

[38]  M. Fathy.  Ca-alginate beads loaded with meloxicam: effect of alginate chemical composition on the properties of the beads and ulcerogenicity of the drug , 2006 .

[39]  Gert Fricker,et al.  Amorphous solid dispersion enhances permeation of poorly soluble ABT-102: true supersaturation vs. apparent solubility enhancement. , 2012, International journal of pharmaceutics.